

## Chapter 2

# Increased Kidney Metabolism as a Pathway to Kidney Tissue Hypoxia and Damage: Effects of Triiodothyronine and Dinitrophenol in Normoglycemic Rats

Malou Friederich-Persson, Patrik Persson, Angelica Fasching, Peter Hansell, Lina Nordquist, and Fredrik Palm

**Abstract** Intrarenal tissue hypoxia is an acknowledged common pathway to end-stage renal disease in clinically common conditions associated with development of chronic kidney disease, such as diabetes and hypertension. In diabetic kidneys, increased oxygen metabolism mediated by mitochondrial uncoupling results in decreased kidney oxygen tension ( $PO_2$ ) and contributes to the development of diabetic nephropathy. The present study investigated whether increased intrarenal oxygen metabolism *per se* can cause intrarenal tissue hypoxia and kidney damage, independently of confounding factors such as hyperglycemia and oxidative stress. Male Sprague–Dawley rats were untreated or treated with either triiodothyronine ( $T_3$ , 10 g/kg bw/day, subcutaneously for 10 days) or the mitochondria uncoupler dinitrophenol (DNP, 30 mg/kg bw/day, oral gavage for 14 days), after which *in vivo* kidney function was evaluated in terms of glomerular filtration rate (GFR, inulin clearance), renal blood flow (RBF, Transonic, PAH clearance), cortical  $PO_2$  (Clark-type electrodes), kidney oxygen consumption ( $QO_2$ ), and proteinuria. Administration of both  $T_3$  and DNP increased kidney  $QO_2$  and decreased  $PO_2$  which resulted in proteinuria. However, GFR and RBF were unaltered by either treatment. The present study demonstrates that increased kidney metabolism *per se* can cause intrarenal tissue hypoxia which results in proteinuria. Increased kidney  $QO_2$  and concomitantly reduced  $PO_2$  may therefore be a mechanism for the development of chronic kidney disease and progression to end-stage renal disease.

---

M. Friederich-Persson (✉) • P. Persson • A. Fasching • P. Hansell • L. Nordquist  
Department Medical Cell Biology, Div. Integrative Physiology, Uppsala University,  
Biomedical Center, D1:3, Husargatan 3, Box 571, SE-751 23 Uppsala, Sweden  
e-mail: Malou.Friederich@mcb.uu.se

F. Palm

Department Medical Cell Biology, Div. Integrative Physiology, Uppsala University,  
Biomedical Center, D1:3, Husargatan 3, Box 571, SE-751 23, Uppsala, Sweden

Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

## 2.1 Introduction

Increased kidney oxygen consumption ( $\text{QO}_2$ ) may result in decreased kidney tissue oxygen tension ( $\text{PO}_2$ ), ultimately resulting in kidney damage. Importantly, intrarenal kidney tissue hypoxia is a proposed pathway to chronic kidney disease and end-stage renal disease in conditions such as diabetes and hypertension [1, 2]. To increase kidney  $\text{QO}_2$ , healthy rats were treated with either dinitrophenol (DNP) or triiodothyronine ( $\text{T}_3$ ). DNP is a chemical uncoupler of mitochondria [3]. By decreasing the mitochondria membrane potential, the process of mitochondria uncoupling reduces formation of oxidative stress but increases mitochondria  $\text{QO}_2$  [4]. Through the nuclear receptor superfamily,  $\text{T}_3$  controls gene transcription and results in increased  $\text{QO}_2$ , mainly via mitochondrial pathways [5]. By utilizing DNP and  $\text{T}_3$ , we create two independent models of increased kidney  $\text{QO}_2$  to investigate whether increased  $\text{QO}_2$  per se can cause intrarenal tissue hypoxia and kidney damage.

## 2.2 Materials and Methods

All animal procedures were carried out according to the National Institutes of Health guidelines and approved by the local animal ethics committee. Normoglycemic male Sprague–Dawley rats (Charles River, Sulzfeld, Germany) received either no treatment, DNP administration (30 mg/kg bw dissolved in 1.5 % methyl cellulose) by oral gavage for 14 days or  $\text{T}_3$  (10  $\mu\text{g/kg}$  bw/day) administered for 10 days by surgically implanted osmotic minipumps (Alzet Company, Cupertino, CA, USA). The animals receiving  $\text{T}_3$  were simultaneously treated with candesartan (1 mg/kg bw in drinking water) in order to minimize the influence of thyroid hormone-induced renin release.

Animals were sedated with sodium thiobutabarbital (Inactin, 120 mg/kg bw i.p.) and placed on a servo-rectally controlled heating pad to maintain body temperature at 37 °C. Tracheotomy was performed to facilitate breathing, and polyethylene catheters were placed in the carotid artery and femoral vein to allow monitoring of mean arterial pressure (MAP, Statham P23dB, Statham Laboratories, Los Angeles, CA, USA), blood sampling, and infusion of saline (5 ml/kg bw/h). The left kidney was exposed by a subcostal flank incision and immobilized in a plastic cup. The left ureter and bladder were catheterized to allow for timed urine sampling and urinary drainage, respectively. After surgery, the animal was allowed to recover for 30 min followed by a 40-min experimental period at the end of which a blood sample was carefully collected from the renal vein in order to calculate arteriovenous differences.

Kidney cortex  $\text{PO}_2$  was measured using Clark-type oxygen electrodes (Unisense, Aarhus, Denmark). Glomerular filtration rate (GFR) was measured by clearance of  $^3\text{H}$ -inulin (185 kBq bolus followed by 185 kBq/kg bw/h; American Radiolabeled Chemicals, St Louis, MO, USA). Renal blood flow (RBF) was measured by Transonic flow probe (Transonic Systems Inc., Ithaca, NY, USA) or clearance by

<sup>14</sup>C-para-aminohippuric acid (PAH, 185 kBq bolus followed by 185 kBq/kg bw/h; American Radiolabeled Chemicals). GFR was calculated as inulin clearance = ([inulin]<sub>urine</sub> \* urine flow) / [inulin]<sub>plasma</sub> and RBF with PAH clearance corrected for PAH extraction and the hematocrit. Total kidney QO<sub>2</sub> (μmol/min) was estimated from the arteriovenous difference in O<sub>2</sub> content (O<sub>2</sub>ct = ([hemoglobin] \* oxygen saturation \* 1.34 + PO<sub>2</sub> \* 0.003)) \* total RBF. Tubular Na<sup>+</sup> transport (T<sub>Na+</sub>, μmol/min) was calculated as follows: T<sub>Na+</sub> = [P<sub>Na+</sub>] \* GFR, where [P<sub>Na+</sub>] is plasma Na<sup>+</sup> concentration. T<sub>Na+</sub> per QO<sub>2</sub> was calculated as T<sub>Na+</sub> / QO<sub>2</sub>.

Statistical comparisons were performed using one-way analysis of variance with Dunnett’s post hoc test. *p* < 0.05 was considered significant and all values are presented as mean ± SEM.

2.3 Results


A decreased body weight and increased kidney weight was observed in T<sub>3</sub>-treated animals compared to controls. GFR, MAP, RBF, Na<sup>+</sup>-excretion, and urinary flow rates were unaffected in both treated groups (Table 2.1). DNP and T<sub>3</sub> administration resulted in increased kidney QO<sub>2</sub> (Fig. 2.1) and decreased intrarenal kidney PO<sub>2</sub> (Fig. 2.2) compared to no treatment. Importantly, the reduced PO<sub>2</sub> resulted in increased proteinuria in both DNP and T<sub>3</sub>-treated animals (Fig. 2.3).


**Table 2.1** Systemic and kidney-specific parameters in control animals receiving either no treatment, dinitrophenol for 14 days, or triiodothyronine for 10 days

	Body weight (g)	Kidney weight (g)	Mean arterial pressure (mmHg)	Urine flow (μl/min)	Renal blood flow (ml/min)	Glomerular filtration rate (ml/min)	Sodium excretion (μmol/min)
No treatment	399 ± 10	1.4 ± 0.1	107 ± 2	3.2 ± 0.8	11.1 ± 0.7	1.6 ± 0.2	0.1 ± 0.1
Dinitrophenol	399 ± 7	1.4 ± 0.0	108 ± 7	4.1 ± 0.8	11.4 ± 1.1	2.1 ± 0.3	0.2 ± 0.1
Triiodothyronine	350 ± 7*	2.7 ± 0.1*	97 ± 4	4.4 ± 0.6	8.1 ± 1.3	1.8 ± 0.3	0.2 ± 0.2


\*Denotes *p* < 0.05 versus control animals

**Fig. 2.1** Kidney oxygen consumption in control animals receiving either no treatment, dinitrophenol for 14 days, or triiodothyronine for 10 days. \* denotes *p* < 0.05 versus control





**Fig. 2.2** Kidney oxygen tension in control animals receiving either no treatment, dinitrophenol for 14 days, or triiodothyronine for 10 days. \* denotes  $p < 0.05$  versus control



**Fig. 2.3** Protein excretion in control animals receiving either no treatment, dinitrophenol for 14 days, or triiodothyronine for 10 days. \* denotes  $p < 0.05$  versus control

## 2.4 Discussion

In the present study, administration of DNP and  $T_3$  to normoglycemic rats increased kidney  $QO_2$ , decreased kidney  $PO_2$ , and increased proteinuria, demonstrating that increased kidney  $QO_2$  is a pathway to kidney damage. Interestingly, treatment with DNP in patients has resulted in proteinuria [6, 7] and patients with untreated Grave's disease also develop proteinuria [8]. It may be argued that DNP is directly nephrotoxic as it is a known environmental toxin. However, this argument cannot apply to  $T_3$  as it is an endogenous hormone. The use of  $T_3$  to establish intrarenal hypoxia verifies that increased kidney  $QO_2$  indeed ultimately results in kidney damage. As  $T_3$  is known to affect the renal angiotensin system and cause hypertension [9], these animals were simultaneously treated with candesartan. It is also unlikely that the observed kidney damage is a result of ATP shortage rather than limited availability of oxygen as the  $Na^+$  excretion is unchanged in both DNP and  $T_3$ -treated animals,

a finding supported by others [10]. We propose that the mechanism to kidney damage is decreased kidney  $\text{PO}_2$  resulting in intrarenal tissue hypoxia, leading to development of proteinuria.

In 1998, it was originally proposed by Fine et al., that the limitation of intrarenal oxygen availability is the key mechanism initiating kidney damage [11]. Since then, this theory has received considerable support, and intrarenal hypoxia is now an acknowledged pathway to chronic kidney disease and end-stage renal disease [1, 2, 12–14]. The oxygen level in the kidney is important because an increased RBF will increase the workload and, therefore, the kidney  $\text{QO}_2$ . This makes increased RBF a very inefficient way to increase renal  $\text{PO}_2$ , and the kidney is therefore vulnerable to alterations in either  $\text{QO}_2$  or oxygen availability. This is further supported by studies reporting that Navajo Indians living at high altitude have increased incidence of end-stage renal disease compared to their corresponding control group at sea level [15]. Also, type 2 diabetic patients at high altitude have increased incidence of diabetic nephropathy despite similar blood pressure and metabolic parameters [16].

In the present study, the utilization of two independent models to create intrarenal tissue hypoxia both resulted in kidney damage evident as increased urinary protein leakage. This clearly demonstrated the importance of intrarenal  $\text{PO}_2$  in maintaining normal kidney function.

## References

1. Nangaku M (2006) Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *J Am Soc Nephrol* 17(1):17–25
2. Mimura I, Nangaku M (2010) The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. *Nat Rev Nephrol* 6(11):667–678
3. Parascandola J (1974) Dinitrophenol and bioenergetics: an historical perspective. *Mol Cell Biochem* 5(1–2):69–77
4. Echtay KS, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA et al (2002) Superoxide activates mitochondrial uncoupling proteins. *Nature* 415(6867):96–99
5. Wrutniak-Cabello C, Casas F, Cabello G (2001) Thyroid hormone action in mitochondria. *J Mol Endocrinol* 26(1):67–77
6. Beinbauer L (1934) Urticaria following the use of dinitrophenol. *WV Med J* 7:466–477
7. Imerman S, Imerman C (1936) Dinitrophenol poisoning with thrombocytopenia, granulopenia, anemia and purpura complicated by lung abscess. *JAMA* 106:1085–1088
8. Weetman AP, Tomlinson K, Amos N, Lazarus JH, Hall R, McGregor AM (1985) Proteinuria in autoimmune thyroid disease. *Acta Endocrinol (Copenh)* 109(3):341–347
9. Perez-Abud R, Rodriguez-Gomez I, Villarejo AB, Moreno JM, Wangenstein R, Tassi M, et al. Salt sensitivity in experimental thyroid disorders in rats. *Am J Physiol Endocrinol Metab* 301(2):E281–E287
10. Evans RG, Goddard D, Eppel GA, O'Connor PM. Stability of tissue  $\text{PO}_2$  in the face of altered perfusion: a phenomenon specific to the renal cortex and independent of resting renal oxygen consumption. *Clin Exp Pharmacol Physiol* 38(4):247–254
11. Fine LG, Orphanides C, Norman JT (1998) Progressive renal disease: the chronic hypoxia hypothesis. *Kidney Int Suppl* 65:S74–S78
12. Nangaku M (2004) Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *Nephron Exp Nephrol* 98(1):e8–e12

13. Singh DK, Winocour P, Farrington K (2008) Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. *Nat Clin Pract Nephrol* 4(4):216–226
14. Palm F, Nordquist L. Renal tubulointerstitial hypoxia: cause and consequence of kidney dysfunction. *Clin Exp Pharmacol Physiol* 38(7):424–430
15. Hochman ME, Watt JP, Reid R, O'Brien KL (2007) The prevalence and incidence of end-stage renal disease in Native American adults on the Navajo reservation. *Kidney Int* 71(9):931–937
16. Sayarlioglu H, Erkoc R, Dogan E, Topal C, Algun E, Erem C et al (2005) Nephropathy and retinopathy in type 2 diabetic patients living at moderately high altitude and sea level. *Ren Fail* 27(1):67–71

Oxygen Transport to Tissue XXXV

Van Huffel, S.; Naulaers, G.; Caicedo, A.; Bruley, D.F.;  
Harrison, D.K. (Eds.)

2013, XXX, 507 p. 170 illus., Hardcover

ISBN: 978-1-4614-7256-8